Analysis of human papillomavirus type‐16 variants in Italian women with cervical intraepithelial neoplasia and cervical cancer
- 13 July 2004
- journal article
- research article
- Published by Wiley in Journal of Medical Virology
- Vol. 74 (1) , 117-126
- https://doi.org/10.1002/jmv.20154
Abstract
Human papillomavirus type 16 (HPV-16) classes (E, AA, As, Af1, Af2) and their variants have different geographic distribution and different degrees of association with cervical lesions. This study was designed to examine HPV-16 variants among Italian women and their prevalence in case patients (affected by invasive cervical carcinoma or cervical intraepithelial neoplasia grade 2–3 and cervical intraepithelial neoplasia grade 1), versus control subjects with normal cervical epithelium (controls). A total of 90 HPV-16 positive cervical samples from women of Italian Caucasian descent have been tested, including 36 invasive cervical carcinomas, 21 with cervical intraepithelial neoplasias grade 2–3, 17 with cervical intraepithelial neoplasia grade 1 and 16 controls. HPV-16 was detected with an E6/E7 gene-specific polymerase chain reaction, and variant HPV-16 classes and subclasses were identified by direct nucleotide sequencing of the region coding for the E6 and the E7 oncoproteins, the MY09/11-amplified highly conserved L1 region, and the long control region (LCR). Among the 90 HPV-16 samples, nine viral variants have been identified belonging to the European (Ep-T350 and E-G350) and non-European (AA and Af-1) branches. The E-G350 is the prevalent variant in all analyzed different disease stages being present in 55.5% of ICC, 52.4% of cervical intraepithelial neoplasias 2–3, 47.1% of cervical intraepithelial neoplasia grade 1, and 50.0% of control samples. The non-European variants AA and Af1, rarely detected in control samples, represent 33.3% of all HPV-16 infections in invasive cervical carcinoma (with a peak of 19.4% and 13.9%, respectively), showing a statistically significant increase in frequency in more advanced lesions (χ2 trend = 7.2; P < 0.05). The prevalence of HPV-16 Ep-T350, however, is higher in controls (43.7%) and in of cervical intraepithelial neoplasia grade 1 (41.2%) than in cervical intraepithelial neoplasia grade 2–3 (28.6%) and in invasive cervical carcinoma (11.1%) cases strongly suggesting lack of progression for pre-neoplastic lesions associated with such variant. The increased frequency of non-European variants in invasive lesions suggests that they are more oncogenic than European variants. This could have implications for future diagnostic and therapeutic strategies. J. Med. Virol. 74:117–126, 2004.Keywords
This publication has 46 references indexed in Scilit:
- Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysisBritish Journal of Cancer, 2003
- Human papillomavirus type‐16 variants in Quechua aboriginals from ArgentinaJournal of Medical Virology, 2003
- Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysisBritish Journal of Cancer, 2003
- Polymorphisms of the Human Leukocyte Antigen DRB1 and DQB1 Genes and the Natural History of Human Papillomavirus InfectionThe Journal of Infectious Diseases, 2002
- Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphismsThe Lancet, 1998
- The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancerNature Medicine, 1995
- Molecular Variant Analysis as an Epidemiological Tool to Study Persistence of Cervical Human Papillomavirus InfectionJNCI Journal of the National Cancer Institute, 1994
- Human Papillomavirus Infection of the CervixObstetrics & Gynecology, 1992
- Human papillomavirus type 16 DNA sequenceVirology, 1985
- A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequencesJournal of Molecular Evolution, 1980